Minimal impact of an iron-fortified lipid-based nutrient supplement on Hb and iron status: a randomised controlled trial in malnourished HIV-positive African adults starting antiretroviral therapy.

What Was Tested

The paper reports a study of Anti-Retroviral Agents, published as a randomized controlled trial.

The researchers analysed information on Fe status and inflammation from a randomised, double blind, controlled phase-III clinical trial in Lusaka, Zambia and Mwanza, Tanzania.

Who Took Part

PubMed indexes the participants as adults, both men and women.

Malnourished patients (n 1815) were recruited at referral to antiretroviral therapy (ART) into a two-stage nutritional rehabilitation programme, randomised to receive a lipid-based nutrient supplement with or without added micronutrients.

Hb, serum C-reactive protein (CRP), serum ferritin and soluble transferrin receptor (sTfR) were measured at recruitment and 6 weeks post-ART.

How the Study Was Run

The design is described as randomized and double-blind.

Because people in this Anti-Retroviral Agents study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Anti-Retroviral Agents study, the assignments were hidden from both participants and investigators until the end.

Fe was included in the intervention arm during the second stage, given from 2 to 6 weeks post-ART.

What Was Measured

Topics PubMed links to this paper include Anemia, Anti-Retroviral Agents, C-Reactive Protein, Dietary Supplements, Ferritins, Food, Fortified and HIV Infections.

The authors tagged it with the keywords Antiretroviral therapy, Hb, Inflammation, Lipid-based nutrient supplement and Transferrin receptor.

What This Means in Plain Language

The paper is a randomized and double-blind study of Anti-Retroviral Agents.

The publication is from 2015 (The British journal of nutrition), a journal based in England.

More context: all human trials.